Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

PURPOSE: This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope covalently linked to keyhole limpet hemocyanin (KLH)) with adjuvant OBI-821 in metastatic breast cancer (MBC). METHODS: At 40...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chiun-Sheng, Yu, Alice L, Tseng, Ling-Ming, Chow, Louis W C, Hou, Ming-Feng, Hurvitz, Sara A, Schwab, Richard B, L Murray, James, Chang, Hsien-Kun, Chang, Hong-Tai, Chen, Shin-Cheh, Kim, Sung-Bae, Hung, Jung-Tung, Ueng, Shir-Hwa, Lee, Su-Hua, Chen, Chwen-Cheng, Rugo, Hope S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380846/
https://www.ncbi.nlm.nih.gov/pubmed/32718986
http://dx.doi.org/10.1136/jitc-2019-000342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380846/
https://www.ncbi.nlm.nih.gov/pubmed/32718986
http://dx.doi.org/10.1136/jitc-2019-000342

Ejemplares similares